The updated Galaxy-1 trial news was not positive, and I said so over the weekend in multiple posts on the SNTA board. I sold off 1/3 of my shares this morning, and will look to lighten up more. It is my view now that the SNTA's fate lies more now in the Enchant-1 breast cancer trial as the NSCLC trial has become more iffy regarding the Galxy-2 phase III trial for NSCLC.
Too bad we didn't get a deal that was cash + AMGN shares rather than all cash. Still, I can't complain about the ONXX buyout.
Well that sucks - 45K in short-term cap gain. At least the large majority of my profit was long-term.
Read today's Yahoo news. Deal with Becton Dickinson to be finalized soon.
Research the company. Tremendous potential.
Follow on Twitter: @AmarantusBio .... 8,488 followers
why don't you just say "margin" instead of arbs and levering up...
still not worth my $200K margin for anything less than 2%. I have used that for GNRC (10% in 2 weeks) and just took a chance on CTB when it went to $30.70. Any positive news will have this up to $34 quickly.
wow, you really don't know eh? I will gladly educate you.
Many firms/funds that trade in arb situations lever up. Meaning, say they had a million dollars (we're using low numbers for simplicity's sake).
In your world, you buy the million dollars worth of shares, stock goes up, you sell for 1%.
In the arb world, they lever that up 10x, so they use $10,000,000 with only $1 million, and that 1% move becomes 10%.
Yes, that kind of leverage is offered (and even more) still to this day. Don't confuse it with the measly 4x your etrade account will allow.
In arbs and special dividend stocks (such as MLPs) that unless something happens to the deal or they consistently support a certain yield, these funds will lever it up, multiplying their return.
The fun happens when a deal falls through, or one of them gets scared triggering a waterfall in the share price. Doesn't happen often, but when it does, it puts the careless firms out of business.
FDA approval for Focalin XR expected for this Quarter...GL
This Low float Stock awaiting 8 FDA approvals and has another 2 Potential Blockbusters ready for Phase 3
Foclian XR alone which is Partnered with Par Pharma will drive IPCI deep into Profitability quickly after Market Launch .There is NO generic version of Focalin XR available on the Market , IPCI & Par will be the first here and its normal that the first generic takes 30%-40% of market share quickly after launch .
5-6 FDA approvals expcted within 12 months .This Gem has everything to move into Double Digits the Market Cap of $40 Million is a Big Joke .
Market Cap:$ 42 M
Cash : $3 M
Shares Out: 21 Mil..(10 Mil Shares held by Insiders/Institutions)
Low Float: 11 M
8 Generic Drug Applications Filed with the FDA
We currently have eight Abbreviated New Drug Applications awaiting FDA approval. These include generics of Focalin XR® Effexor XR®, Protonix ®' Glucophage ® XR,Seroquel XR®, Lamictaf® XR Keppra XR® and Pristiq® .Together, these products represent approximately $4.78 of branded and generic sales.
Our lead product, a generic version of Focal in XR®, is partnered with Par Pharmaceuticals Inc., a top ten U.S.pharmaceutical company.As a result of a settlement with the innovator company, we expect to marketing of our generic versions ofFocalin XR® upon approval. We have a ten year profit-sharing agreement with Par for the sale of a generic version of Focal in XR® in the U.S.,which commences with the commercial launch of the product by Par .
Nothing you can do except hope they do not settle/close by then. It probably will not happen until late November/early December anyway.